Literature DB >> 19878140

H2 haplotype at chromosome 17q21.31 protects against childhood sexual abuse-associated risk for alcohol consumption and dependence.

Elliot C Nelson1, Arpana Agrawal, Michele L Pergadia, Jen C Wang, John B Whitfield, F Scott Saccone, Jason Kern, Julia D Grant, Andrew J Schrage, John P Rice, Grant W Montgomery, Andrew C Heath, Alison M Goate, Nicholas G Martin, Pamela A F Madden.   

Abstract

Animal research supports a central role for corticotropin-releasing factor (CRF) in actions of ethanol on brain function. An examination of alcohol consumption in adolescents reported a significant genotype x environment (G x E) interaction involving rs1876831, a corticotropin-releasing hormone receptor 1 (CRHR1) polymorphism, and negative events. CRHR1 and at least four other genes are located at 17q21.31 in an extremely large block of high linkage disequilibrium resulting from a local chromosomal inversion; the minor allele of rs1876831 is contained within the H2 haplotype. Here, we examine whether G x E interactions involving this haplotype and childhood sexual abuse (CSA) are associated with risk for alcohol consumption and dependence in Australian participants (n = 1128 respondents from 476 families) of the Nicotine Addiction Genetics project. Telephone interviews provided data on DSM-IV alcohol dependence diagnosis and CSA and enabled calculation of lifetime alcohol consumption factor score (ACFS) from four indices of alcohol consumption. Individuals reporting a history of CSA had significantly higher ACFS and increased risk for alcohol dependence. A significant G x E interaction was found for ACFS involving the H2 haplotype and CSA (P < 0.017). A similar G x E interaction was associated with protective effects against alcohol dependence risk (odds ratio 0.42; 95% confidence interval 0.20-0.89). For each outcome, no significant CSA-associated risk was observed in H2 haplotype carriers. These findings support conducting further investigation of the H2 haplotype to determine the gene(s) responsible. Our results also suggest that severe early trauma may prove to be an important clinical covariate in the treatment of alcohol dependence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19878140      PMCID: PMC3068622          DOI: 10.1111/j.1369-1600.2009.00181.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  74 in total

1.  The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication.

Authors:  Kenneth S Kendler; Jonathan W Kuhn; Jen Vittum; Carol A Prescott; Brien Riley
Journal:  Arch Gen Psychiatry       Date:  2005-05

2.  No evidence of CRHR1 gene involvement in progressive supranuclear palsy.

Authors:  Jaume Campdelacreu; Carles Gaig; Mario Ezquerra; Esteban Muñoz; Maria Jose Martí; Francesc Valldeoriola; Eduardo Tolosa
Journal:  Neurosci Lett       Date:  2006-09-28       Impact factor: 3.046

3.  Genetic effects on alcohol dependence risk: re-evaluating the importance of psychiatric and other heritable risk factors.

Authors:  Valerie S Knopik; Andrew C Heath; Pamela A F Madden; Kathleen K Bucholz; Wendy S Slutske; Elliot C Nelson; Dixie Statham; John B Whitfield; Nicholas G Martin
Journal:  Psychol Med       Date:  2004-11       Impact factor: 7.723

4.  Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population.

Authors:  Jaakko Lappalainen; Evgeny Krupitsky; Mikhail Remizov; Sofia Pchelina; Anastaisa Taraskina; Edwin Zvartau; Lucia K Somberg; Jonathan Covault; Henry R Kranzler; John H Krystal; Joel Gelernter
Journal:  Alcohol Clin Exp Res       Date:  2005-04       Impact factor: 3.455

5.  Genomic architecture of human 17q21 linked to frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region.

Authors:  Marc Cruts; Rosa Rademakers; Ilse Gijselinck; Julie van der Zee; Bart Dermaut; Tim de Pooter; Peter de Rijk; Jurgen Del-Favero; Christine van Broeckhoven
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

6.  Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia.

Authors:  Purnima Desai Sundar; Chang-En Yu; Weiva Sieh; Ellen Steinbart; Ralph M Garruto; Kiyomitsu Oyanagi; Ulla-Katrina Craig; Thomas D Bird; Ellen M Wijsman; Douglas R Galasko; Gerard D Schellenberg
Journal:  Hum Mol Genet       Date:  2006-12-21       Impact factor: 6.150

7.  The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression.

Authors:  Nathan A Gillespie; John B Whitfield; Ben Williams; Andrew C Heath; Nicholas G Martin
Journal:  Psychol Med       Date:  2005-01       Impact factor: 7.723

8.  Interactive effects of the serotonin transporter 5-HTTLPR polymorphism and stressful life events on college student drinking and drug use.

Authors:  Jonathan Covault; Howard Tennen; Stephen Armeli; Tamlin S Conner; Aryeh I Herman; Antonius H N Cillessen; Henry R Kranzler
Journal:  Biol Psychiatry       Date:  2006-08-22       Impact factor: 13.382

9.  The transcription factor nerve growth factor-inducible protein a mediates epigenetic programming: altering epigenetic marks by immediate-early genes.

Authors:  Ian C G Weaver; Ana C D'Alessio; Shelley E Brown; Ian C Hellstrom; Sergiy Dymov; Shakti Sharma; Moshe Szyf; Michael J Meaney
Journal:  J Neurosci       Date:  2007-02-14       Impact factor: 6.167

10.  Haplotype-specific expression of exon 10 at the human MAPT locus.

Authors:  Tara M Caffrey; Catharine Joachim; Silvia Paracchini; Margaret M Esiri; Richard Wade-Martins
Journal:  Hum Mol Genet       Date:  2006-11-03       Impact factor: 6.150

View more
  37 in total

Review 1.  Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse.

Authors:  George R Breese; Rajita Sinha; Markus Heilig
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

Review 2.  Studying longitudinal trajectories in animal models of psychiatric illness and their translation to the human condition.

Authors:  Carlos A Driscoll; Christina S Barr
Journal:  Neurosci Res       Date:  2015-08-12       Impact factor: 3.304

Review 3.  Translational and reverse translational research on the role of stress in drug craving and relapse.

Authors:  Rajita Sinha; Yavin Shaham; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2011-04-15       Impact factor: 4.530

Review 4.  Pharmacogenetic approaches to the treatment of alcohol addiction.

Authors:  Markus Heilig; David Goldman; Wade Berrettini; Charles P O'Brien
Journal:  Nat Rev Neurosci       Date:  2011-10-20       Impact factor: 34.870

Review 5.  Corticotropin releasing factor: a key role in the neurobiology of addiction.

Authors:  Eric P Zorrilla; Marian L Logrip; George F Koob
Journal:  Front Neuroendocrinol       Date:  2014-01-20       Impact factor: 8.606

Review 6.  The limbic-hypothalamic-pituitary-adrenal axis and the development of alcohol use disorders in youth.

Authors:  Ty S Schepis; Uma Rao; Hardik Yadav; Bryon Adinoff
Journal:  Alcohol Clin Exp Res       Date:  2011-01-11       Impact factor: 3.455

Review 7.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

Review 8.  The influence of gene-environment interactions on the development of alcoholism and drug dependence.

Authors:  Mary-Anne Enoch
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

Review 9.  Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Authors:  Eric P Zorrilla; Markus Heilig; Harriet de Wit; Yavin Shaham
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

Review 10.  Genetic influences on the development of alcoholism.

Authors:  Mary-Anne Enoch
Journal:  Curr Psychiatry Rep       Date:  2013-11       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.